TAVR (SAPIEN family)
Revenue Exposure
TAVR is the dominant revenue driver at 74% of 2025 net sales, down modestly from 77% in 2023
Relevance 98·Dependency 85·Confidence 98
Source evidence
“Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.”
Edwards SAPIEN 3 Ultra RESILIA valve
Revenue Exposure
TAVR, the largest product group at $4.5B, grew primarily on SAPIEN 3 Ultra RESILIA sales in the US and Europe.
Relevance 95·Dependency 85·Confidence 95
Source evidence
“primarily due to higher sales of the Edwards SAPIEN 3 Ultra RESILIA valve in the United States and Europe”
Hospital systems
Customer Exposure
Sales depend on hospital systems adequately staffing catheterization laboratories; large hospital decisions have meaningfully adversely impacted sales.
Relevance 85·Dependency 80·Confidence 90
Source evidence
“we rely on hospital systems to be able to hire staff and have available facilities, including catheterization laboratories, to perform procedures using our products”
bovine tissue
Raw Material Dependency
Pericardial tissue valves depend on bovine tissue sourced only from closely controlled US and Australian suppliers; BSE concerns or supply disruption would directly affect tissue valve products.
Relevance 85·Dependency 70·Confidence 95
Source evidence
“We obtain bovine tissue only from closely controlled sources within the United States and Australia.”
EVOQUE tricuspid valve replacement system
Revenue Exposure
TMTT's 56.4% growth was driven by PASCAL and EVOQUE sales in the US and Europe.
Relevance 85·Dependency 60·Confidence 93
Source evidence
“higher sales of our PASCAL transcatheter edge-to-edge repair system and EVOQUE tricuspid valve replacement system in the United States and Europe”
Medtronic plc
Competitive Exposure
Medtronic is a primary competitor in both TAVR and Surgical product lines
Relevance 85·Dependency 40·Confidence 95
Source evidence
“In TAVR, our primary competitors include Medtronic plc ("Medtronic") and Abbott Laboratories ("Abbott").”
Abbott Laboratories
Competitive Exposure
Abbott is a primary competitor in TAVR, the sole named primary competitor in TMTT, and a primary competitor in Surgical
Relevance 85·Dependency 40·Confidence 95
Source evidence
“In TMTT, our primary competitor is Abbott”
U.S. national coverage determination for TAVR
Demand Driver
Restrictive U.S. NCD requirements for TAVR procedures can limit marketing success and procedure volumes.
Relevance 80·Dependency 70·Confidence 90
Source evidence
“restrictive requirements in the U.S. national coverage determination for transcatheter aortic valve replacement procedures”
FDA and other regulatory authorities
Legal Exposure
Manufacture and sterilization are highly complex due to rigorous regulatory requirements; supplier changes require significant effort under FDA rules.
Relevance 80·Dependency 70·Confidence 90
Source evidence
“A change or addition to our vendors could require significant effort due to the rigorous regulations and requirements of the FDA and other regulatory authorities”
Cardiovascular disease burden
Demand Driver
Progressive cardiovascular disease, the world's number-one cause of death, underpins demand for structural heart therapies and future growth in heart failure treatment
Relevance 80·Dependency 60·Confidence 90
Source evidence
“Cardiovascular disease is the number-one cause of death in the world and is the top disease in terms of health care spending in nearly every country.”
Single-source suppliers
Supplier Dependency
Certain supplies and services are purchased from single sources; replacing vendors is difficult under FDA regulations, creating supply interruption risk.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“we purchase certain supplies and services from single sources for reasons of quality assurance, cost-effectiveness, availability, constraints resulting from regulatory requirements, and other reasons”
Hospital facilities and staffing capacity
Competitive Exposure
Multiple new technologies including Edwards' own TAVR and TMTT products compete for the same hospital facilities and staffing, constraining procedure volumes and sales.
Relevance 75·Dependency 65·Confidence 85
Source evidence
“more products, including Edwards’ own products, are competing for the same facilities and staffing within hospitals”
long-term implantable devices
Legal Exposure
Long-term implantable devices expose the company to product liability claims that may exceed insurance coverage limits.
Relevance 75·Dependency 50·Confidence 90
Source evidence
“product liability or other claims may exceed insurance coverage limits, fines, and penalties”
TMTT (PASCAL/EVOQUE/SAPIEN M3)
Revenue Exposure
TMTT is the fastest-growing product group, rising from 4% to 9% of net sales between 2023 and 2025
Relevance 75·Dependency 35·Confidence 95
Source evidence
“Sales of our TMTT products represented 9%, 7%, and 4% of our net sales in 2025, 2024, and 2023, respectively.”
Healthcare reimbursement and regulatory approval systems
Regulatory Exposure
Where Edwards markets products is influenced by existence of, or potential for, adequate reimbursement by national healthcare systems; approvals and adoption depend on clinical evidence
Relevance 70·Dependency 60·Confidence 85
Source evidence
“Where we choose to market our products is also influenced by the existence of, or potential for, adequate reimbursement to hospitals and other providers by national healthcare systems.”
Direct sales forces and independent distributors
Customer Exposure
Sales reach hospitals worldwide via direct sales forces and independent distributors, supplemented by GPO and national/regional buying group contracts
Relevance 70·Dependency 55·Confidence 93
Source evidence
“our distribution system consists of several direct sales forces as well as independent distributors”
OECD Pillar Two global minimum tax
Tax Exposure
Pillar Two 15% global minimum tax added ~$19.1M of tax expense in 2025 and raised the effective tax rate to 17.0%; ongoing enactment risk remains.
Relevance 70·Dependency 50·Confidence 93
Source evidence
“Many countries are implementing some or all of the Organisation for Economic Co-operation and Development's Base Erosion and Profit Shifting Pillar Two ("Pillar Two") rules that impose a global minimum tax of 15% on reported profits”
Euro strengthening against USD increased non-US net sales by $26.7 million in 2025; FX also affects international manufacturing and operating costs, partially hedged.
Relevance 70·Dependency 40·Confidence 92
Source evidence
“foreign currency exchange rate fluctuations increased net sales outside of the United States by $26.7 million primarily due to the strengthening of the Euro against the United States dollar”
Surgical Structural Heart
Revenue Exposure
Surgical tissue heart valves contributed 17% of 2025 net sales (18% in 2024, 19% in 2023)
Relevance 70·Dependency 30·Confidence 95
Source evidence
“Sales of our surgical tissue heart valve products represented 17%, 18%, and 19% of our net sales in 2025, 2024, and 2023, respectively.”
Raw material cost increases/inflation
Cost Driver
Significant raw material cost increases from inflationary pressure, supply constraints, tariffs, or regulatory changes could adversely impact operating results.
Relevance 65·Dependency 50·Confidence 85
Source evidence
“any significant increases in the cost of raw materials, whether due to inflationary pressure, supply constraints, the imposition of tariffs, regulatory changes, or otherwise, could adversely impact our operating results”
US and foreign healthcare fraud and abuse laws
Regulatory Exposure
Anti-kickback, false claims, and physician-relationship restrictions affect sales practices; violations risk fines, imprisonment, and exclusion from governmental healthcare programs.
Relevance 65·Dependency 40·Confidence 90
Source evidence
“Any alleged or actual violations of these laws may subject us to government investigations and significant criminal or civil sanctions and may impact our ability to sell products in certain jurisdictions”
OECD Pillar Two
Regulatory Exposure
Pillar Two implementation and the treatment of the U.S. tax regime as a qualified side-by-side system could materially impact the tax provision.
Relevance 60·Dependency 45·Confidence 90
Source evidence
“could impact our provision for income taxes”
Artificial intelligence (AI)
Technology Dependency
Edwards uses AI and emerging technologies in various facets of operations; failure to effectively and timely utilize them could adversely impact results.
Relevance 55·Dependency 45·Confidence 85
Source evidence
“We use AI and other emerging technologies in various facets of our operations and our business.”
Australia
Revenue Exposure
Australia is one of only two disclosed sources (with the US) of bovine tissue used in pericardial tissue valves.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“We obtain bovine tissue only from closely controlled sources within the United States and Australia.”
United States
Supplier Dependency
The United States is one of only two disclosed sources of bovine tissue used in pericardial tissue valves.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“We obtain bovine tissue only from closely controlled sources within the United States and Australia.”
FTC / Hart Scott Rodino
Legal Exposure
Company accrued a payment and agreed to conditions to resolve an FTC dispute over failure to file an HSR notice for the JC Medical acquisition.
Relevance 55·Dependency 30·Confidence 85
Source evidence
“the Company has accrued for a payment and has agreed to certain other conditions to resolve a dispute with the FTC regarding its decision not to file a Hart Scott Rodino notice for its acquisition of JC Medical, Inc.”
GDPR imposes stringent EU data protection requirements with significant penalties for noncompliance on processing of patient and customer data.
Relevance 50·Dependency 35·Confidence 90
Source evidence
“The GDPR imposes stringent EU data protection requirements and provides for significant penalties for noncompliance.”